FDA Hears Arguments on Behind-the-Counter Drugs

The U.S. Food and Drug Administration yesterday held a hearing to weigh the possibility of introducing a new class of drugs that would be sold from behind the counter.

WASHINGTON — The U.S. Food and Drug Administration yesterday held a hearing to weigh the possibility of introducing a new class of drugs that would be sold from behind the counter. These medications would require consultation with pharmacists rather than doctors, similar to the way the emergency contraceptive Plan B is sold now. Representing retail pharmacy at the hearing was Steve Giroux, president of the National Community Pharmacists Association, Alexandria, Va., which recently found that

Register to view the full article

TAGS: News